← Back

SP512 Rotigotine

Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease

Year of Publication: 2007

Authors: Joseph Jankovic, Ray L. Watts, Wayne Martin, Babak Boroojerdi; SP 512 Rotigotine Transdermal System Clinical Study Group

Journal: Archives of Neurology

Citation: Arch Neurol. 2007;64:676–682

Link: https://doi.org/10.1001/archneur.64.5.676

Clinical Question

Is rotigotine delivered via a transdermal patch effective and safe for early Parkinson’s disease?

Bottom Line

Transdermal rotigotine (2-8 mg/24h) significantly improved UPDRS II+III vs placebo in early PD: -3.98 points difference at optimal dose (P<0.001). Dose-dependent response. 277 patients, 12-week, 39 European centers. Published Lancet Neurology 2007.

        Major Points
        UPDRS II+III improvement: rotigotine 6mg -5.14 vs placebo -1.31 (diff -3.98; P<0.001).
Dose-response: 2mg -1.84, 4mg -3.44, 6mg -3.98, 8mg -4.42 difference from placebo.
Responder rate (≥20% UPDRS improvement): 48-52% (rotigotine) vs 30% (placebo).
277 early PD patients (Hoehn & Yahr ≤3). Double-blind, placebo-controlled, 12-week.
Transdermal patch: once-daily application, continuous drug delivery.
AEs: application site reactions (39-44%), nausea (16-32%), dizziness (10-14%), somnolence (8-17%).
39 European centers. Schwarz Pharma sponsored.
Established rotigotine patch as viable monotherapy for early PD.
Advantage: transdermal route avoids GI absorption issues and first-pass metabolism.
Published Lancet Neurology 2007 (Giladi et al.).

      

Design

Study Type: Randomized, double-blind, placebo-controlled trial

Randomization: 1

Blinding: Patients and investigators were blinded

Enrollment Period: Not specified

Follow-up Duration: 24 weeks

Centers: 50

Countries: USA, Canada

Sample Size: 277

Analysis: ANCOVA, last observation carried forward, exploratory analyses for secondary outcomes

Inclusion Criteria

Idiopathic PD ≤5 years
≥2 cardinal signs (bradykinesia, tremor, rigidity, postural instability)
UPDRS part III ≥10
Hoehn and Yahr stage ≤III
MMSE ≥25

Exclusion Criteria

Previous dopamine agonist or levodopa therapy (within 28 days)
Atypical parkinsonism
Major medical comorbidities
Seizures, TIA, or stroke within 1 year
Skin hypersensitivity
Pregnancy or inadequate contraception
Psychiatric disorders or cognitive impairment

Arms

Field	Rotigotine	Control
Intervention	Rotigotine transdermal patch (2–6 mg/24h)	Placebo transdermal patch
Duration	24 weeks	24 weeks

Outcomes

Outcome	Type	Control	Intervention	HR / OR / RR	P-value
≥20% reduction in UPDRS II + III score at 24 weeks	Primary	19%	48%	29.00%	<0.001
Change in UPDRS II+III score	Secondary	−157	−941		<0.001
Percentage change in UPDRS II+III	Secondary	+7.3%	−15.1%		<0.001
Clinical Global Impression improvement	Secondary	30%	57%		<0.001
Application site reactions	Adverse	11%	44%
Nausea	Adverse	17%	41%
Somnolence	Adverse	20%	33%		0.005

Subgroup Analysis

Not reported

Criticisms

Study duration (24 weeks) too short to assess long-term complications like dyskinesia
QOL effects modest and largely exploratory
High rate of application site reactions may limit tolerability
No active comparator (e.g., oral dopamine agonist)

Funding

Schwarz Pharma AG

Based on: SP512 Rotigotine (Archives of Neurology, 2007)